Valued at USD 2.80 billion in 2020, the contrast media market is projected to reach USD 5.33 billion by 2028, growing at a CAGR of 8.6% during the forecast period 2021–2028, according to Polaris Market Research. The rising prevalence of long-term complex diseases with high comorbidities has increased the number of imaging tests, lifting demand for contrast agents. Key players include Lantheus Medical Imaging, Inc., Bayer AG, General Electric, Nano Therapeutics Pvt. Ltd., Guerbet, Bracco Diagnostic, Inc., iMax, and Trivitron Healthcare.

Imaging Volumes Drive the Contrast Media Market

The report explains that long-term complex diseases with high comorbidities have increased the use of imaging tests, including ultrasounds, CT scans, X-rays, and other advanced technologies. These tests help identify the need for surgery in interventional procedures, and pre-operative scans before surgeries have also boosted the use of contrast media. Diagnostic imaging procedures are described as a necessary first step in deciding whether a patient should undergo surgery or another treatment, which supports sustained demand.

The report's market dynamics outline lists the increase in prevalence of targeted diseases and the ageing population across the globe as growth drivers, and product recalls as a restraint, which are important considerations for manufacturers planning supply and quality assurance.

Iodinated Agents Hold the Largest Product Share

By product, the market covers iodinated, barium-based, gadolinium-based, and microbubble agents. Iodinated contrast media accounted for the largest revenue share in 2020, a position the report attributes to excellent radio-opacity and lower toxicity compared with other agents. Iodinated media are mostly used for radiological examination. The microbubble segment, by contrast, is expected to witness a lucrative growth rate over the assessment period, which the report attributes to its smaller size and high echogenicity.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/contrast-media-contrast-agents-market

Modality Insights: X-ray/CT Leads

By modality, the X-ray/CT segment accounted for the largest share in 2020, owing to its wide acceptance and cost efficiency. X-ray/CT contrast media comprise primarily iodinated and barium-based contrast agents, which are used in diagnostic procedures for numerous chronic diseases and are comparatively less expensive than alternatives. The MRI segment is projected to see lucrative growth over the assessment period, while ultrasound is the third modality covered.

Application Segments

The report segments the market by application into cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders, and others. This structure allows manufacturers and healthcare buyers to align product development and procurement with the clinical areas that rely most on imaging.

Regional Overview

North America held a dominant share of the global market in 2020. The report points to well-established hospital facilities with equipped diagnostic equipment, along with patient awareness of early diagnosis for cancer, rare diseases, and hereditary disorders. The regional scope also covers Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria), Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea), Latin America (Brazil, Mexico, Argentina), and the Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa).

Competitive Landscape

Companies are introducing new contrast agents to diversify their portfolios. Bracco Diagnostics introduced Gadoteridol to image neck and head lesions using MRI, and GE Healthcare previously introduced Clariscan in the European region. In October 2023, Guerbet received marketing authorization for Elucirem (Gadopiclenol) from the European Commission. The report's company profiles cover Bayer AG, General Electric, Guerbet, Bracco Diagnostic, Inc., Nano Therapeutics Pvt. Ltd., Lantheus Medical Imaging, Inc., iMax, and Trivitron Healthcare, each including company overview, financial performance, product and services benchmarking, and recent developments.

Outlook for Contrast Media Stakeholders

With the contrast media market valued at USD 2.80 billion in 2020 and projected to reach USD 5.33 billion by 2028, manufacturers and healthcare providers should track imaging volumes, product mix, and regional demand. Iodinated agents and X-ray/CT modalities currently hold the leading positions, while MRI and microbubble products are flagged for lucrative growth.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market